Structure and function of telomeres/telomerase and their role in preleukaemia and haematologic malignancies

HAEMA

Volumn 6, Issue 1, 2003, Pages 35-47

  Koutroumba, Paraskevi ^a   Polychronopoulou, Sophia ^a   Haidas, Stavros ^a  

^a AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Hematologic neoplasias; Leukemogenesis; Preleukemia; Senescence; Telomerase; Telomeres

Indexed keywords

DNA POLYMERASE; NUCLEOPROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELOMERASE;

CELL PROLIFERATION; CHROMOSOME; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; EOSINOPHILIA; EUKARYOTIC CELL; FANCONI ANEMIA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HODGKIN DISEASE; HUMAN; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOGENESIS; PRELEUKEMIA; PROGNOSIS; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; SENESCENCE; STRUCTURE ACTIVITY RELATION; TELOMERE;

EID: 0037498479     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585-621.
2. Greider CW. Telomeres, telomerase and senescence. Bioessays 1990; 12: 363-369.
3. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutation Res 1991; 256: 271-282.
4. Krupp G, Klapper W, Parwaresch R. Cell proliferation, carcinogenesis and diverse mechanisms of telomerase regulation. Cell Mol Life Sci 2000; 57: 464-486.
5. Ishikawa F. Aging clock: the watchmaker's masterpiece. Cell Mol Life Sci 2000; 57: 698-704.
6. Cerni C. Telomeres, telomerase and myc. An update. Mutat Res 2000; 462: 31-47.
7. Wynford-Thomas D. Cellular senescence and cancer. J Pathol 1999; 187: 100-111.
8. Planas-Silva MD, Weinberg RA. The restriction point and control of cell proliferation. Curr Opin Cell Biol 1997; 9: 768-772.
9. Parwaresch R, Rudolph P. The cell cycle-theory and application to cancer. Oncologie 1996; 19: 464-472.
10. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem Sci 1998; 23: 291-296.
11. Zakian V. Telomeres: Beginning to understand the end. Science 1995; 270: 1601-1607.
12. Makarov VL, Hirose Y, Langmore JP. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 1997; 88: 657-666.
13. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989; 59: 521-529.
14. Liu J-P. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 1999; 13: 2091-2104.
15. Kim NW, Piatyszec MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
16. Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569-573.
17. Greider CW. Telomeres do D-Loop-T-Loop. Cell 1999; 97: 419-422.
18. Kirk KE, Harmon BP, Reichardt IK et al. Block in anaphase chromosome separation caused by a telomerase template mutation. Science 1997; 275: 1478-1481.
19. Greider CW. Telomere length regulation. Annu Rev Biochem 1996; 65: 337-365.
20. Blackburn EH. Switching and signaling at the telomere. Cell 2001; 106: 661-673.
21. Moyzis RK, Buckingham JM, Cram LS et al. A highly conserved repetitive DNA sequence (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 1988; 85: 6622-6626.
22. Kim S, Kaminker P, Campisi J, Telomeres, aging and cancer: In search of a happy ending. Oncogene 2002; 21: 503-511.
23. Wilkie AO, Higgs DR, Rack KA et al. Stable length polymorphism of up to 260 kb at the tip of the short arm of human chromosome 16. Cell 1991; 64: 595-606.
24. Klobutcher LA, Swanton MT, Donini P, Prescott DM. All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3′-terminus. Proc Natl Acad Sci USA 1981; 78: 3015-3019.
25. Chong L, van Steensel B, Broccoli D et al. A human telomeric protein. Science 1995; 270: 1663-1667.
26. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusion. Cell 1998; 92: 401-413.
27. Harrington L, McPhail T, Mar V et al. A mammalian telomerase-associated protein. Science 1997; 275: 973-977.
28. LaBranche H, Dupuis S, Ben-David Y et al. Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase. Nat Genet 1998; 19: 199-202.
29. Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly (ADP-ribose) polymerase at human telomeres. Science 1998; 282: 1484-1487.
30. Harley CB, Futcher AB, Greider CM. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 458-460.
31. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene 2002; 21: 564-579.
32. Iwama H, Ohyashiki K, Ohyashiki JH et al. Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals. Hum Genet 1998; 102: 397-402.
33. Cooke HJ, Smith BA. Variability at the telomeres of the human X/Y pseudoautomosal region. Cold Spring Harbor Symp Quant Biol 1986; 51: 213-219.
34. Hastie N, Dempster M, Dunlop M et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990; 346: 866-868.
35. Griffith JD, Comeau L, Rosenfield S et al. Mammalian telomeres end in a large duplex loop. Cell 1999; 97: 503-514.
36. Munoz-Jordan JL, Cross GA, de Lange T, Griffith JD. T-loops at trypanosome telomeres. EMBO J 2001; 20: 579-588.
37. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena. Cell 1985; 43: 405-413.
38. Greider CW, Blackburn EH. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987; 51: 887-898.
39. Feng J, Funk WD, Wang S-S et al. The RNA component of human telomerase. Science 1995; 269: 1236-1241.
40. Harrington L, Zhou W, McPhail T. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev 1997; 11: 3109-3115.
41. Collins K, Kobayashi R, Greider CW. Purification of Tetrahymena telomerase and cloning of genes encoding the two protein components of the enzyme. Cell 1995; 81: 677-686.
42. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase is required for telomere repeat synthesis. Nature 1989; 337: 331-337.
43. Blasco MA, Funk W, Villeponteau B, Greider CW. Functional characterization and developmental regulation of mouse telomerase RNA. Science 1995; 269: 1267-1270.
44. Yu GL, Bradley JD, Attardi LD. In vivo alteration of telomere sequences caused by mutated Tetrahymena telomerase RNAs. Nature 1990; 344: 126-132.
45. Nakamura TM, Morin GB, Chapman KB et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277: 955-959.
46. Lingner J, Hughes TR, Shevchenko A et al. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997; 276: 561-567.
47. Lee MS, Blackburn EH. Sequence-specific DNA primer effects on telomerase polymerization activity. Mol Cell Biol 1993; 13: 6586-6599.
48. Melek M, Greene EC, Shippen DE. Processing of non-telomeric 3' ends by telomerase: default template alignment and endonucleolytic cleavage. Mol Cell Biol 1996; 16: 3437-3445.
49. Hiyama K, Hirai Y, Kyoizumi S et al. Activation of telomerase in human lymphocytes and haematopoietic progenitor cells. J Immunol 1995; 155: 3711-3715.
50. Taylor RS, Ramirez RD, Ogoshi M et al. Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol 1996; 106: 759-765.
51. Hiyama E, Hiyama K, Tatsumoto N et al. Telomerase activity in human intestine. Int J Oncol 1996; 9: 453-458.
52. Ramirez RD, Wright WE, Shay JW, Taylor RS. Telomerase activity concentrates in the mitotically active segments of human hair follicles. J Invest Dermatol 1997; 108: 113-117.
53. Brien TP, Kallakury BV, Lowry CV et al. Telomerase activity in benign endometrium and endometrial carcinoma. Cancer Res 1997; 57: 2760-2764.
54. Shay JW, Werbin H, Wright WE. Telomeres and telomerase in human leukaemias. Leukemia 1996; 10: 1255-1261.
55. Ducrest A-L, Szutorisz H, Lingner J, Nabholz M. Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002; 21: 541-552.
56. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organisation of the gene and characterization of the promoter. Hum Mol Genet 1999; 8: 137-142.
57. Wang J, Xie LY, Allan S et al. Myc activates telomerase. Genes Dev 1998; 12: 1769-1774.
58. Wu KJ, Grandori C, Amacker M et al. Direct activation of TERT transcription by c-myc. Nat Genet 1999; 21: 220-224.
59. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papilloma-virus type 16. Nature 1996; 380: 79-82.
60. Burger AM, Fiebig HH, Kuettel MR et al. Effect of oncogene expression on telomerase activation and telomere length in human endothelial, fibroblast and prostate epithelial cells. Int J Oncol 1998; 13: 1043-1048.
61. Rhim JS, Tsai WP, Chen ZQ et al. A human vascular endothelial cell model to study angiogenesis and tumorigenesis. Carcinogenesis 1998; 19: 673-681.
62. Mandal M, Kumar R. Bcl-2 modulates telomerase activity. J Biol Chem 1997; 272: 14183-14187.
63. Xu HJ, Zhou Y, Ji W et al. Reexpession of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 1997; 15: 2589-2596.
64. Kallassy M, Martel N, Damour O et al. Growth arrest of immortalized human keratinocytes and suppression of telomerase activity by p21WAF1 gene expression. Mol Carcinogen 1998; 21: 26-36.
65. van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997; 385: 740-743.
66. Metz T, Harris AW, Adams JM. Absence of p53 allows direct immortalization of haematopoietic cells by the myc and raf oncogenes. Cell 1995; 82: 29-36.
67. Li H, Zhao L, Yang Z et al. Telomerase is controlled by protein kinase C alpha in human breast cancer cells. J Biol Chem 1998; 273: 33436-33442.
68. Li H, Zhao L, Funder JW, Liu J-P. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol Chem 1997; 272: 16729-16732.
69. Kang SS, Kwon T, Kwon DY et al. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999; 274: 13085-13090.
70. Blasco MA, Lee H-W, Hande MD et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25-34.
71. Lee HW, Blasco MA, Gottlieb GJ et al. Essential role of mouse telomerase in highly proliferative organs. Nature 1998; 392: 569-574.
72. Rudolph KL, Chang S, Lee HW et al. Longevity, stress response and cancer in aging telomerase-deficient mouse. Cell 1999; 96: 701-712.
73. Chan S W-L, Blackburn EH. New ways not to make ends meet: telomerase, DNA damage proteins and heterochromatin. Oncogene 2002; 21: 553-563.
74. Chin L, Artandi SE, Shen Q et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 527-538.
75. Bryan TM, Englezou A, Gupta J et al. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14: 4240-4248.
76. Biessmann H, Mason JM. Telomere maintenance without telomerase. Chromosoma 1997; 106: 63-69.
77. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in haematologic neoplasia. Oncogene 2002; 21: 680-687.
78. Counter CM, Gupta J, Harley CB et al. Telomerase activity in normal leukocytes and in haematologic malignancies. Blood 1995; 85: 2315-2320.
79. Vaziri H, Dragowska W, Allosopp RC et al. Evidence for a mitotic clock in human haematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994; 91: 9857-9860.
80. Norrback K-F, Dahlenborg K, Carlsson R, Roos G. Telomerase activity in normal B-lymphocytes and non-Hodgkin's lymphomas. Blood 1996; 88: 222-229.
81. Weng N-P, Levine BL, June CH, Hodes RJ. Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med 1996; 183: 2471-2479.
82. Hu BT, Lee SC, Marin E et al. Telomerase is up-regulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro. J Immunol 1997; 159: 1068-1071.
83. Son NH, Murray S, Yanovski J et al. Lineage-specific telomere shortening and unaltered capacity for telomerase expression in human T and B lymphocytes with age. J Immunol 2000; 165: 1191-1196.
84. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 1994; 91: 2900-2904.
85. Nilsson P, Mehle C, Remes K, Roos G. Telomerase activity in vivo in human malignant haematopoietic cells. Oncogene 1994; 9: 3043-3048.
86. Norrback K-F., Enblad G, Erlanson M et al. Telomerase activity in Hodgkin's disease. Blood 1998; 92: 567-573.
87. Li B, Yang J, Andrews C et al. Telomerase activity in preleukaemia and acute myelogenous leukaemia. Leuk Lymphoma 2000; 36: 579-587.
88. Ohyashiki JH, Ohyashiki K, Fujimura T et al. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 1994; 54: 3557-3560.
89. Engelhardt M, Mackenzie K, Drullinsky P et al. Telomerase activity and telomere length in acute and chronic leukaemia, pre and post-ex vivo culture. Cancer Res 2000; 60: 610-617.
90. Leteurtre F, Li X, Guardiola P et al. Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br J of Haematol 1999; 105: 883-893.
91. Ohyashiki JH, Ohyashiki K, Iwama K et al. Clinical implications of telomerase activity levels in acute leukaemia. Clin Cancer Res 1997; 3: 619-625.
92. Zhang W, Piatyszek MA, Kobayashi T et al. Telomerase activity in human acute myelogenous leukaemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res 1996; 2: 799-803.
93. Engelhardt M, Ozkaynak MF, Drullinsky P et al. Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia 1998; 12: 13-24.
94. Ohyashiki K, Ohyashiki JH, Iwama S et al. Telomerase activity and cytogenetic changes in chronic myeloid leukaemia with disease progression. Leukemia 1997; 11: 190-194.
95. Trentin L, Ballon G, Ometto L et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J of Haematol 1999; 106: 662-668.
96. Remes K, Norrback K-F, Rosenquist R et al. Telomere length and telomerase activity in malignant lymphomas at diagnosis and relapse. Br J of Cancer 2000; 82: 601-607.
97. Hiyama E, Hiyama K. Clinical utility of telomerase in cancer. Oncogene 2002; 21: 643-649.
98. Ohyashiki K, Ohyashiki JH, Toyama K. Technical improvement in determining telomerase activity in haematologic neoplasias: a possibility of single cell determination of telomerase activity. Hum Cell 1996; 9: 295-300.
99. Herbert B-S, Pitts AE, Baker SI et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci, 1999; 96: 14276-14281.
100. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996; 16: 53-65.
101. Corey RD. Telomerase inhibition, oligonucleotides and clinical trials. Oncogene 2002; 21: 631-637.
102. Jean-Louis M, Claude H. G-quadruplex DNA: a target for drug design. Nat Med 1998; 4: 1366-1367.
103. Wynn RF, Cross MA, Hatton C et al. Accelerated telomere loss in young recipients of allogeneic bone-marrow transplants. Lancet 1998; 351: 178-181.
104. Akiyama M, Hoshi Y, Sakurai H et al. Changes of telomere length in children after haematopoietic stem cells transplantation. Bone Marrow Transplant 1998; 21: 167-171.
105. Rufer N, Brummendorf TH, Chpuis B et al. Accelerated telomere shortening in haematological lineages is limited to the first year following stem cell transplantation. Blood 2001; 97: 575-577.
106. Thomas M, Yang L, Hornsby PJ. Formation of functional tissue from transplanted adenocortical cells expresses telomerase reverse transcriptase. Nat Biotechnol 2000; 18: 39-42.
107. Shay JW, Wright WE. The reactivation of telomerase activity in cancer progression. Trends Genet 1996; 12: 129-131.